在接受类固醇治疗的COVID-19重症患者中发生的二次感染
Alex K Pearce1, Qais Zawaydeh2, W Cameron McGuire1
1Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, University of California, San Diego, La Jolla, CA, USA.
Science progress
|October 30, 2023
概括
在重症COVID-19患者的葡萄糖皮质激素治疗没有显著改变二次感染的风险. 这项研究发现,在类固醇治疗和非类固醇治疗组中,二次感染和死亡率相似.
科学领域:
- 关键护理医学 关键护理医学
- 传染病 传染病 传染病
- 药理学 药理学是指药理学的学科.
背景情况:
- 二次感染对患有严重COVID-19的患者构成重大风险.
- 葡萄糖皮质类药物用于管理严重的COVID-19,但它们对二次感染风险的影响尚不清楚.
研究的目的:
- 为了调查接受葡萄糖皮质类药物治疗的重症COVID-19患者中二次感染的发生率.
- 为了确定葡萄糖皮质激素的使用是否会影响该群体的二次感染率或死亡率.
主要方法:
- 来自两个学术医疗中心的107名危急COVID-19患者的回顾性分析.
- 用葡萄糖皮质类药物治疗的患者 (n=31) 和未使用葡萄糖皮质类药物治疗的患者 (n=76) 之间的二次感染率和死亡率的比较.
- 使用匹配对分析和多变量逻辑回归.
主要成果:
- 第二次感染发生在45.2%的类固醇接受者和46.1%的非接受者 (p=0.968) 中.
- 呼吸道感染是最常见的,大肠杆菌和黄金葡萄球菌是常见的病原体.
- 类固醇组的死亡率为16.1%,对照组为23.7% (p=0.388).
结论:
- 在重症COVID-19患者中,二次感染很常见.
- 葡萄糖皮质激素治疗没有显著影响该队列中二次感染或死亡率的发生率.
更多相关视频
相关概念视频
Pulmonary Tuberculosis I
246
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
246
Pneumonia III: Complications and Assessment
242
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
242
COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Pneumonia IV: Management
338
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
338


